Company intelligence / Profile preview
Excalipoint Therapeutics
Shanghai, Shanghai, Chinaexcalipoint.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Excalipoint is a clinical-stage biotech developing next-generation T-cell engager (TCE) therapies. Its lead program, EXP011, is a tri-specific antibody targeting DLL3, CD3, and 4-1BB, which entered Phase 1/2 clinical trials in October 2025 for the treatment of small-cell lung cancer and neuroendocrine tumors.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Tri-specific antibodyT-cell engagerMultispecific antibodyMonoclonal antibodyProbody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Lepu Biopharma
Beyond the preview
Go deeper on Excalipoint Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Excalipoint Therapeutics.